{"organizations": [], "uuid": "5c2970ea0b40d7f7cba2ec6742274a53828d6e6b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-allena-pharmaceuticals-initiates-f/brief-allena-pharmaceuticals-initiates-first-phase-3-trial-for-alln-177-in-patients-with-enteric-hyperoxaluria-idUSASB0C8YB", "country": "US", "domain_rank": 408, "title": "BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.152, "site_type": "news", "published": "2018-03-06T21:18:00.000+02:00", "replies_count": 0, "uuid": "5c2970ea0b40d7f7cba2ec6742274a53828d6e6b"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-allena-pharmaceuticals-initiates-f/brief-allena-pharmaceuticals-initiates-first-phase-3-trial-for-alln-177-in-patients-with-enteric-hyperoxaluria-idUSASB0C8YB", "ord_in_thread": 0, "title": "BRIEF-Allena Pharmaceuticals Initiates First Phase 3 Trial For ALLN-177 In Patients With Enteric Hyperoxaluria", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allena pharmaceuticals inc", "sentiment": "negative"}, {"name": "brief-allena pharmaceuticals initiates first phase", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "bla", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Allena Pharmaceuticals Inc:\n* ALLENA PHARMACEUTICALS INITIATES FIRST PHASE 3 TRIAL FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA\n* ALLENA PHARMACEUTICALS INC - ‍TOPLINE DATA FROM PHASE 3 TRIAL FOR ALLN-177 EXPECTED IN SECOND HALF OF 2019​\n* ALLENA PHARMACEUTICALS INC - ‍EXPECTS TO INITIATE URIROX-2 IN SECOND HALF OF 2018, CONSISTENT WITH PRIOR GUIDANCE​\n* ALLENA - ‍INITIATION OF URIROX-1 TRIAL FOLLOWS MULTIPLE INTERACTIONS WITH FDA AFTER WHICH FDA CONFIRMED IT HAD NO COMMENTS ON PROTOCOL​\n* ALLENA PHARMACEUTICALS INC - ‍CONTINUES TO ENGAGE WITH FDA TO FINALIZE DESIGN OF URIROX-2​\n* ALLENA - ENGAGING FDA TO DISCUSS PURSUING ACCELERATED APPROVAL PATHWAY FOR PLANNED BLA SUBMISSION FOR ALLN-177 IN PATIENTS WITH ENTERIC HYPEROXALURIA​\n* ALLENA - ‍BELIEVES PHASE 3 PROGRAM, IF SUCCESSFUL, COULD BE ELIGIBLE FOR MAA VIA CONDITIONAL APPROVAL PATHWAY​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T21:18:00.000+02:00", "crawled": "2018-03-07T19:27:12.000+02:00", "highlightTitle": ""}